Stemline Therapeutics Stock Price, News & Analysis (NASDAQ:STML)

$14.45 -0.25 (-1.70 %)
(As of 11/24/2017 04:00 PM ET)
Previous Close$14.70
Today's Range$14.45 - $15.15
52-Week Range$5.50 - $15.15
Volume132,050 shs
Average Volume278,148 shs
Market Capitalization$371.72 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.07

About Stemline Therapeutics (NASDAQ:STML)

Stemline Therapeutics logoStemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Receive STML News and Ratings via Email

Sign-up to receive the latest news and ratings for STML and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:STML
CUSIPN/A
Phone646-502-2311

Debt

Debt-to-Equity RatioN/A
Current Ratio4.57%
Quick Ratio4.57%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.04 million
Price / Sales351.39
Cash FlowN/A
Price / CashN/A
Book Value$2.62 per share
Price / Book5.52

Profitability

Trailing EPS($2.57)
Net Income$-38,300,000.00
Net Margins-4,689.63%
Return on Equity-75.50%
Return on Assets-64.20%

Miscellaneous

Employees29
Outstanding Shares25,290,000

Frequently Asked Questions for Stemline Therapeutics (NASDAQ:STML)

What is Stemline Therapeutics' stock symbol?

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

How were Stemline Therapeutics' earnings last quarter?

Stemline Therapeutics, Inc. (NASDAQ:STML) released its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.18. The biopharmaceutical company had revenue of $0.30 million for the quarter, compared to analysts' expectations of $0.30 million. Stemline Therapeutics had a negative return on equity of 75.50% and a negative net margin of 4,689.63%. View Stemline Therapeutics' Earnings History.

Where is Stemline Therapeutics' stock going? Where will Stemline Therapeutics' stock price be in 2017?

6 brokerages have issued 1 year target prices for Stemline Therapeutics' stock. Their predictions range from $16.00 to $41.00. On average, they anticipate Stemline Therapeutics' stock price to reach $33.40 in the next year. View Analyst Ratings for Stemline Therapeutics.

What are Wall Street analysts saying about Stemline Therapeutics stock?

Here are some recent quotes from research analysts about Stemline Therapeutics stock:

  • 1. According to Zacks Investment Research, "Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. " (7/18/2017)
  • 2. HC Wainwright analysts commented, "Bio-Path reported 1Q17 with operating expenses of $2M which were offset by a change in non-cash warrant liability for a net loss of $0.4M. Bio-Path ended the period with $7.1M in cash, sufficient runway to the end of the year." (5/15/2017)
  • 3. Cowen Inc analysts commented, "STML reported 1Q17 financials and provided a pipeline update." (5/12/2017)

Who are some of Stemline Therapeutics' key competitors?

Who are Stemline Therapeutics' key executives?

Stemline Therapeutics' management team includes the folowing people:

  • Ivan Bergstein M.D., Chairman of the Board, President, Chief Executive Officer
  • Kenneth Hoberman, Chief Operating Officer
  • David G. Gionco, Chief Accounting Officer, Vice President - Finance
  • Ron Bentsur, Independent Director
  • Eric L. Dobmeier, Independent Director
  • Alan S. Forman, Independent Director
  • Kenneth J. Zuerblis, Independent Director

Who owns Stemline Therapeutics stock?

Stemline Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Lyon Street Capital LLC (2.14%), Dimensional Fund Advisors LP (0.87%), C WorldWide Group Holding A S (0.64%), Bank of New York Mellon Corp (0.33%), Cowen Inc. (0.15%) and California State Teachers Retirement System (0.14%). Company insiders that own Stemline Therapeutics stock include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Institutional Ownership Trends for Stemline Therapeutics.

Who sold Stemline Therapeutics stock? Who is selling Stemline Therapeutics stock?

Stemline Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp and California State Teachers Retirement System. Company insiders that have sold Stemline Therapeutics company stock in the last year include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Insider Buying and Selling for Stemline Therapeutics.

Who bought Stemline Therapeutics stock? Who is buying Stemline Therapeutics stock?

Stemline Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Lyon Street Capital LLC, C WorldWide Group Holding A S, Dimensional Fund Advisors LP, Cowen Inc. and Empire Life Investments Inc.. View Insider Buying and Selling for Stemline Therapeutics.

How do I buy Stemline Therapeutics stock?

Shares of Stemline Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Stemline Therapeutics' stock price today?

One share of Stemline Therapeutics stock can currently be purchased for approximately $14.45.

How big of a company is Stemline Therapeutics?

Stemline Therapeutics has a market capitalization of $371.72 million and generates $1.04 million in revenue each year. The biopharmaceutical company earns $-38,300,000.00 in net income (profit) each year or ($2.57) on an earnings per share basis. Stemline Therapeutics employs 29 workers across the globe.

How can I contact Stemline Therapeutics?

Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]


MarketBeat Community Rating for Stemline Therapeutics (STML)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  324
MarketBeat's community ratings are surveys of what our community members think about Stemline Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Stemline Therapeutics (NASDAQ:STML)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.562.562.603.00
Ratings Breakdown: 2 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $33.40$32.60$32.60$32.60
Price Target Upside: 141.16% upside232.65% upside302.47% upside295.15% upside

Consensus Price Target History for Stemline Therapeutics (NASDAQ:STML)

Price Target History for Stemline Therapeutics (NASDAQ:STML)

Analysts' Ratings History for Stemline Therapeutics (NASDAQ:STML)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017HC WainwrightReiterated RatingBuy$38.00N/AView Rating Details
10/31/2017Cowen IncReiterated RatingBuyN/AView Rating Details
5/25/2017Jefferies Group LLCReiterated RatingBuy$16.00MediumView Rating Details
5/11/2017WedbushBoost Price TargetOutperform$33.00 -> $40.00HighView Rating Details
3/20/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$41.00MediumView Rating Details
12/7/2016Roth CapitalReiterated RatingBuy$32.00N/AView Rating Details
3/18/2016Rodman & RenshawReiterated RatingBuyN/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Stemline Therapeutics (NASDAQ:STML)

Earnings by Quarter for Stemline Therapeutics (NASDAQ:STML)

Earnings History by Quarter for Stemline Therapeutics (NASDAQ STML)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.48)($0.66)$0.30 million$0.30 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.45)($0.67)$0.30 million$0.30 millionViewN/AView Earnings Details
5/9/2016Q116($0.59)($0.51)$121.43 million$205.65 millionViewN/AView Earnings Details
3/14/2016Q4($0.57)($0.58)$0.15 million$0.21 millionViewN/AView Earnings Details
11/6/2015Q315($0.59)($0.53)$0.10 million$0.21 millionViewN/AView Earnings Details
8/10/2015Q2($0.41)($0.58)$0.10 million$0.12 millionViewN/AView Earnings Details
5/11/2015Q1($0.45)($0.46)$0.09 million$0.12 millionViewN/AView Earnings Details
3/13/2015($0.60)($0.53)$0.07 million$0.12 millionViewN/AView Earnings Details
11/12/2014Q314($0.58)($0.53)$0.07 million$0.07 millionViewN/AView Earnings Details
8/14/2014($0.71)($0.47)$0.07 million$0.07 millionViewN/AView Earnings Details
5/22/2014($0.72)($0.70)$0.07 million$0.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Stemline Therapeutics (NASDAQ:STML)
2017 EPS Consensus Estimate: ($2.19)
2018 EPS Consensus Estimate: ($2.16)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.42)($0.42)($0.42)
Q2 20171($0.47)($0.47)($0.47)
Q3 20171($0.62)($0.62)($0.62)
Q4 20171($0.68)($0.68)($0.68)
Q1 20181($0.54)($0.54)($0.54)
Q2 20181($0.54)($0.54)($0.54)
Q3 20181($0.55)($0.55)($0.55)
Q4 20181($0.53)($0.53)($0.53)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Stemline Therapeutics (NASDAQ:STML)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Stemline Therapeutics (NASDAQ STML)

Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 46.54%
Insider Trades by Quarter for Stemline Therapeutics (NASDAQ:STML)
Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)

Insider Trades by Quarter for Stemline Therapeutics (NASDAQ STML)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/28/2017David GioncoInsiderSell6,486$6.99$45,337.14View SEC Filing  
2/28/2017Ivan BergsteinCEOSell17,980$6.99$125,680.20View SEC Filing  
2/28/2017Kenneth HobermanCOOSell8,027$6.99$56,108.73View SEC Filing  
2/27/2017David GioncoCAOSell3,500$6.97$24,395.00View SEC Filing  
2/27/2017Ivan BergsteinCEOSell7,500$6.97$52,275.00View SEC Filing  
2/27/2017Kenneth HobermanCOOSell4,000$6.97$27,880.00View SEC Filing  
2/16/2017Ivan BergsteinCEOSell3,652$6.42$23,445.84View SEC Filing  
2/16/2017Kenneth HobermanCOOSell1,508$6.42$9,681.36View SEC Filing  
1/19/2017David GioncoInsiderSell3,593$11.46$41,175.78View SEC Filing  
1/10/2017Kenneth HobermanCOOSell9,110$13.82$125,900.20View SEC Filing  
3/8/2016David GioncoCAOSell1,148$5.32$6,107.36View SEC Filing  
3/8/2016Ivan BergsteinCEOSell5,537$5.34$29,567.58View SEC Filing  
3/8/2016Kenneth HobermanCOOSell2,412$5.34$12,880.08View SEC Filing  
2/17/2016Ivan BergsteinCEOSell3,244$4.46$14,468.24View SEC Filing  
2/17/2016Kenneth HobermanCOOSell1,503$4.54$6,823.62View SEC Filing  
1/20/2016David GioncoCAOSell3,217$4.82$15,505.94View SEC Filing  
11/30/2015Ivan BergsteinCEOSell12,235$8.20$100,327.00View SEC Filing  
4/27/2015Eric K RowinskyInsiderSell10,824$15.77$170,694.48View SEC Filing  
3/19/2015Kenneth HobermanCOOSell17,307$16.43$284,354.01View SEC Filing  
1/20/2015David GioncoCAOSell3,311$14.22$47,082.42View SEC Filing  
11/26/2014Ivan BergsteinCEOSell11,974$14.40$172,425.60View SEC Filing  
9/3/2014Ivan BergsteinCEOBuy2,000$11.05$22,100.00View SEC Filing  
9/2/2014Kenneth HobermanCOOBuy2,000$10.99$21,980.00View SEC Filing  
9/2/2014Kenneth J ZuerblisDirectorBuy1,000$11.14$11,140.00View SEC Filing  
5/30/2013Kenneth J ZuerblisDirectorBuy3,000$16.01$48,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Stemline Therapeutics (NASDAQ STML)

Source:
DateHeadline
Kite Pharma (KITE) versus Stemline Therapeutics (STML) Head to Head ReviewKite Pharma (KITE) versus Stemline Therapeutics (STML) Head to Head Review
www.americanbankingnews.com - November 17 at 7:22 AM
Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO)Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO)
feeds.benzinga.com - November 16 at 7:49 AM
Stemline Therapeutics, Inc. (STML) Stock Rating Reaffirmed by HC WainwrightStemline Therapeutics, Inc. (STML) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - November 12 at 12:58 AM
Ophthotech Corporation (OPHT) vs. Stemline Therapeutics (STML) Head-To-Head ContrastOphthotech Corporation (OPHT) vs. Stemline Therapeutics (STML) Head-To-Head Contrast
www.americanbankingnews.com - November 10 at 3:40 AM
Stemline Therapeutics Reports Third Quarter 2017 Financial ResultsStemline Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 7:12 PM
Stemline Therapeutics reports 3Q lossStemline Therapeutics reports 3Q loss
finance.yahoo.com - November 9 at 7:12 PM
Here's Why Stemline Therapeutics Inc. Jumped 23% Higher in OctoberHere's Why Stemline Therapeutics Inc. Jumped 23% Higher in October
finance.yahoo.com - November 7 at 11:22 AM
Heres Why Stemline Therapeutics Inc. Jumped 23% Higher in OctoberHere's Why Stemline Therapeutics Inc. Jumped 23% Higher in October
www.fool.com - November 6 at 12:36 PM
Stemline Therapeutics, Inc. (STML) Given Consensus Rating of "Buy" by BrokeragesStemline Therapeutics, Inc. (STML) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 6 at 3:46 AM
ETFs with exposure to Stemline Therapeutics, Inc. : November 2, 2017ETFs with exposure to Stemline Therapeutics, Inc. : November 2, 2017
finance.yahoo.com - November 4 at 10:54 PM
Stemline Therapeutics (STML) Phase 2 Trial of SL-401 in BPDCN Meets Primary EndpointStemline Therapeutics (STML) Phase 2 Trial of SL-401 in BPDCN Meets Primary Endpoint
www.streetinsider.com - November 2 at 9:21 AM
Stemline Therapeutics, Inc. (STML) Price Target Raised to $38.00Stemline Therapeutics, Inc. (STML) Price Target Raised to $38.00
www.americanbankingnews.com - November 1 at 11:04 AM
FDAs Efforts to Accelerate New Drug Development is a Big Bonus for Biotech and Pharma Stocks - PR Newswire (press release)FDA's Efforts to Accelerate New Drug Development is a Big Bonus for Biotech and Pharma Stocks - PR Newswire (press release)
www.prnewswire.com - November 1 at 9:17 AM
Noteworthy Tuesday Option Activity: SHLD, AMBA, STML - NasdaqNoteworthy Tuesday Option Activity: SHLD, AMBA, STML - Nasdaq
www.nasdaq.com - November 1 at 9:17 AM
The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33% - Motley FoolThe Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33% - Motley Fool
www.fool.com - November 1 at 9:17 AM
Stemline Announces Four SL-401 Presentations at Upcoming ASH MeetingStemline Announces Four SL-401 Presentations at Upcoming ASH Meeting
finance.yahoo.com - November 1 at 9:17 AM
The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33%The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33%
www.fool.com - October 31 at 4:56 PM
Stemline Therapeutics (STML) "Buy" Rating Reiterated at Cowen and CompanyStemline Therapeutics' (STML) "Buy" Rating Reiterated at Cowen and Company
www.americanbankingnews.com - October 31 at 3:25 PM
Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary EndpointStemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint
finance.yahoo.com - October 31 at 10:02 AM
Stemline Therapeutics, Inc. (STML) Scheduled to Post Quarterly Earnings on MondayStemline Therapeutics, Inc. (STML) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 9:36 AM
Stemline Therapeutics, Inc. (STML) Given Average Recommendation of "Buy" by BrokeragesStemline Therapeutics, Inc. (STML) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 12 at 4:46 AM
Stemline Therapeutics Stock Sees Short Interest Drop 17%Stemline Therapeutics Stock Sees Short Interest Drop 17%
www.thestreet.com - October 11 at 3:29 PM
Biotechs Leading the way in Life Altering Cancer Therapies - PR Newswire (press release)Biotech's Leading the way in Life Altering Cancer Therapies - PR Newswire (press release)
www.prnewswire.com - September 20 at 9:37 AM
Biotechs Leading the way in Life Altering Cancer Therapies - PR Newswire (press release)Biotech's Leading the way in Life Altering Cancer Therapies - PR Newswire (press release)
www.prnewswire.com - September 20 at 9:37 AM
Stemline Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire (press release)Stemline Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire (press release)
www.globenewswire.com - September 20 at 9:37 AM
Stemline Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire (press release)Stemline Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire (press release)
www.globenewswire.com - September 20 at 9:37 AM
Stemline Therapeutics to Present at Upcoming Investor ConferencesStemline Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - September 20 at 9:37 AM
Stemline Therapeutics to Present at Upcoming Investor ConferencesStemline Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - September 20 at 9:37 AM
Stemline Therapeutics, Inc. (STML) Receives Consensus Recommendation of "Buy" from BrokeragesStemline Therapeutics, Inc. (STML) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 17 at 4:40 AM
Stemline Therapeutics, Inc. (STML) Rating Reiterated by HC WainwrightStemline Therapeutics, Inc. (STML) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - September 12 at 9:24 AM
Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017
finance.yahoo.com - September 11 at 7:15 AM
Stemline Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment ConferenceStemline Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 8 at 8:50 AM
ETFs with exposure to Stemline Therapeutics, Inc. : September 1, 2017ETFs with exposure to Stemline Therapeutics, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 9:12 AM
Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO CongressStemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress
feeds.benzinga.com - August 30 at 8:19 PM
Stemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Stemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 1:27 PM
Stemline Therapeutics, Inc. (STML) Given Average Rating of "Buy" by BrokeragesStemline Therapeutics, Inc. (STML) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 23 at 4:44 AM
Stemline Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare ConferenceStemline Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 15 at 7:25 AM
Stemline Therapeutics, Inc. (NASDAQ:STML) Expected to Post Q3 2017 Earnings of ($0.62) Per ShareStemline Therapeutics, Inc. (NASDAQ:STML) Expected to Post Q3 2017 Earnings of ($0.62) Per Share
www.americanbankingnews.com - August 14 at 2:06 AM
Stemline Therapeutics Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)Stemline Therapeutics Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 10 at 8:19 AM
Stemline Therapeutics Inc (NASDAQ:STML) Announces  Earnings Results, Misses Expectations By $0.18 EPSStemline Therapeutics Inc (NASDAQ:STML) Announces Earnings Results, Misses Expectations By $0.18 EPS
www.americanbankingnews.com - August 9 at 3:48 PM
Stemline Therapeutics reports 2Q lossStemline Therapeutics reports 2Q loss
finance.yahoo.com - August 9 at 7:54 AM
Stemline Therapeutics Reports Second Quarter 2017 Financial ResultsStemline Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 7:11 AM
Stemline Therapeutics, Inc. (NASDAQ:STML) Given Consensus Recommendation of "Buy" by BrokeragesStemline Therapeutics, Inc. (NASDAQ:STML) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 29 at 7:45 AM
Stemline Therapeutics, Inc. (NASDAQ:STML) Given Consensus Rating of "Buy" by AnalystsStemline Therapeutics, Inc. (NASDAQ:STML) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - July 4 at 11:28 AM
Stemline Therapeutics (STML) Announces SL-401 Updated Stage 1 & 2 Data from Ongoing Pivotal Trial in BPDCN ... - StreetInsider.comStemline Therapeutics (STML) Announces SL-401 Updated Stage 1 & 2 Data from Ongoing Pivotal Trial in BPDCN ... - StreetInsider.com
www.streetinsider.com - June 25 at 6:43 AM
Stemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN and Safety Experience Across Multiple Indications, Today at EHAStemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN and Safety Experience Across Multiple Indications, Today at EHA
feeds.benzinga.com - June 23 at 10:17 AM
Stemline Therapeutics to Present at the Jefferies 2017 Healthcare ... - GlobeNewswire (press release)Stemline Therapeutics to Present at the Jefferies 2017 Healthcare ... - GlobeNewswire (press release)
globenewswire.com - June 6 at 11:18 PM
Stemline Therapeutics to Present at the Jefferies 2017 Healthcare ConferenceStemline Therapeutics to Present at the Jefferies 2017 Healthcare Conference
feeds.benzinga.com - June 6 at 7:46 AM
Stemline Therapeutics (STML) to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at EHAStemline Therapeutics (STML) to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at EHA
www.streetinsider.com - May 19 at 12:51 PM
Stemline Therapeutics (STML) to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 ... - StreetInsider.comStemline Therapeutics (STML) to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 ... - StreetInsider.com
www.streetinsider.com - May 18 at 12:55 PM

Social Media

Financials

Chart

Stemline Therapeutics (NASDAQ STML) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.